陈秀, 任胜祥, 李雪飞, 李嘉瑜, 任睿欣, 周彩存. 白蛋白紫杉醇治疗多线治疗后晚期非小细胞肺癌的疗效分析[J]. 中国肿瘤临床, 2012, 39(22): 1824-1827. DOI: 10.3969/j.issn.1000-8179.2012.22.032
引用本文: 陈秀, 任胜祥, 李雪飞, 李嘉瑜, 任睿欣, 周彩存. 白蛋白紫杉醇治疗多线治疗后晚期非小细胞肺癌的疗效分析[J]. 中国肿瘤临床, 2012, 39(22): 1824-1827. DOI: 10.3969/j.issn.1000-8179.2012.22.032
shu
Xiu CHEN, Shengxiang REN, Xuefei LI, Jiayu LI, Ruixin REN, Caicun ZHOU. Efficacy of Nab-Paclitaxel for Advanced Non-Small Cell Lung Cancer after Failure of Multi-line Chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(22): 1824-1827. DOI: 10.3969/j.issn.1000-8179.2012.22.032
Citation: Xiu CHEN, Shengxiang REN, Xuefei LI, Jiayu LI, Ruixin REN, Caicun ZHOU. Efficacy of Nab-Paclitaxel for Advanced Non-Small Cell Lung Cancer after Failure of Multi-line Chemotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(22): 1824-1827. DOI: 10.3969/j.issn.1000-8179.2012.22.032
shu

白蛋白紫杉醇治疗多线治疗后晚期非小细胞肺癌的疗效分析

Efficacy of Nab-Paclitaxel for Advanced Non-Small Cell Lung Cancer after Failure of Multi-line Chemotherapy

    摘要
  • 摘要:
      目的   探讨白蛋白紫杉醇治疗既往接受过三线或三线以上治疗的晚期非小细胞肺癌患者的临床疗效和不良反应。
      方法   回顾性分析2010年8月至2012年6月确诊为晚期非小细胞肺癌的16例患者，接受白蛋白紫杉醇化疗的疗效以及不良反应。白蛋白紫杉醇130 mg/m2 （d1，d8，d15）单药静脉化疗，每4周为1个疗程，每2个周期评价疗效。
      结果   16例患者中，男性13例，女性3例；中位年龄57（40~75）岁；腺癌8例，鳞癌4例，其他4例；吸烟10例，不吸烟6例。全组患者中，部分缓解（partial response，PR）3例（18.75%），疾病稳定（stable disease，SD）5例（32.25%），疾病进展（progressive disease，PD）8例（50.00%）。客观缓解率（objective response rate，ORR）18.75%，疾病控制率（disease control rate，DCR）50.00%。中位疾病进展时间（median time to progression，MTTP）为2.15个月。主要不良反应是脱发（37.50%）、中性粒细胞减少（31.25%）和末梢神经毒性（12.50%）。
      结论   白蛋白紫杉醇在经过多线抗肿瘤治疗后的晚期非小细胞肺癌治疗中仍显示出一定疗效，不良反应可以接受，值得进一步进行大样本研究加以验证。

     

    Abstract:
      Objective   This study aimed to investigate the clinical efficacy and adverse effects of nab-paclitaxel in patients with advanced non-small cell lung cancer who underwent at least third-line chemotherapy.
      Methods   Clinical data of 16 advanced non-small cell lung cancer patients (13 males and 3 females; median age = 57 years, range = 40~75 years) who received nab-paclitaxel as a single agent between August 2010 and June 2012 were collected, and the curative and adverse effects of the compound were evaluated. Of the 16 patients, 8 had adenocarcinoma, 4 had squamous carcinoma, and 4 were found to have other tumors. Moreover, 10 patients were smokers. All patients were treated with 130 mg/m2 nab-paclitaxel on days 1, 8, and 15. The cycle was repeated every 4 weeks. Clinical efficacy was evaluated every two cycles.
      Results   Three patients (18.75%) achieved partial response, 5 (32.25%) had a stable disease, and 8 (50.00%) had a progressive disease. The objective response rate was 18.75%, and the disease control rate was 50.00%. The median time to progression was 2.15 months. The major adverse reactions included alopecia (37.50%), neutropenia (31.25%), and sensory neuropathy (12.50%).
      Conclusion   Nab-paclitaxel has curative effects, and its adverse effects are tolerable. Further research with a larger sample size is warranted to confirm these results.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回